Breast Cancer Proteomics and Molecular Heterogeneity
Cancer Trials Ireland
1,780 participants
Feb 1, 2013
OBSERVATIONAL
Conditions
Summary
Primary objective: The primary objective is to define the proteomic and molecular characteristics of primary and recurrent/ metastatic breast tumours with special focus on the expression of S100 protein and the estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2) genes Secondary objective: * To expand our understanding of the complex molecular pathways dictating the progression of breast cancer and their response to different treatment regimes. * To relate proteomic findings to survival data * To identify potential serum markers of breast cancer progression
Eligibility
Inclusion Criteria8
- Patients diagnosed with primary breast cancer attending hospital for the resection of their tumour tissue
- Or
- Patients with suspected or confirmed recurrent or metastatic breast cancer (Patient has a history of a biopsy- or surgically- (i.e. pathologically) confirmed primary breast cancer) attending hospital for the resection/biopsy and/or treatment of tumour tissue
- Or
- Patient with suspected (but not necessarily biopsy confirmed) newly diagnosed stage 4 breast cancer attending hospital for the resection/biopsy and/or treatment of their tumour tissue
- Patients receiving neoadjuvant treatment are also eligible (if applicable)
- Patients have to be ≥ 18 years of age
- Patients must be able to give informed consent
Locations(6)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT01840293